The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with primary breast cancer (BC; GBG 45).
B. Conrad
No relevant relationships to disclose
N. Harbeck
No relevant relationships to disclose
G. Von Minckwitz
Research Funding - Bayer
M. Wuellner
No relevant relationships to disclose
M. Warm
No relevant relationships to disclose
K. Schwedler
No relevant relationships to disclose
B. Gerber
Honoraria - AstraZeneca; GlaxoSmithKline; Novartis; Roche; Sanofi
Research Funding - Novartis
I. Schrader
No relevant relationships to disclose
H. Eidtmann
No relevant relationships to disclose
K. Mehta
No relevant relationships to disclose
S. Loibl
No relevant relationships to disclose